CLINUVEL PHARMACEUTICALS LIMITED - Announcements

Market Cap $727.1M Add to my watchlist

Healthcare Biotechnology

Clinuvel Pharmaceuticals Limited is an Australia-based global specialty pharmaceutical... Clinuvel Pharmaceuticals Limited is an Australia-based global specialty pharmaceutical company. The Company is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the USA, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). The Company’s pharmaceuticals product development includes PRENUMBRA and NEURACTHEL. Its PhotoCosmetics product development includes CYACELLE and DNA Repair Assist and Melanogenesis. PRENUMBRA is a formulation of afamelanotide designed to provide a flexible dose in identified patient groups. NEURACTHEL is a novel formulation of the melanocortin adrenocorticotropic hormone (ACTH).More

Announcements

Filter Results

All Price Sensitive Only

CUV	Canadian New Drug Submission for SCENESSE in EPP filed	PRICE SENSITIVE	01/10/24	78.42KB	Share
CUV	Update - Notification of buy-back - CUV		27/09/24	15.7KB	Share
CUV	Update - Notification of buy-back - CUV		26/09/24	15.7KB	Share
CUV	SCENESSE data to be presented at global porphyria conference		20/09/24	67.18KB	Share
CUV	Update - Notification of buy-back - CUV		19/09/24	15.7KB	Share
CUV	Notice of Annual General Meeting/Proxy Form		13/09/24	446.2KB	Share
CUV	Change of AGM Time of Meeting		13/09/24	62.86KB	Share
CUV	Initial Director's Interest Notice - Pearl Grimes		10/09/24	233.67KB	Share
CUV	Initial Director's Interest Notice - Guy van Dievoet		10/09/24	230.29KB	Share
CUV	Initial Director's Interest Notice - Matthew Pringle		10/09/24	230.05KB	Share
CUV	Update - Notification of buy-back - CUV		10/09/24	15.7KB	Share
CUV	Chair's letter to Shareholders		09/09/24	103.42KB	Share
CUV	CLINUVEL Board Renewal, Expansion		06/09/24	80.49KB	Share
CUV	Update - Notification of buy-back - CUV		06/09/24	15.7KB	Share
CUV	Update - Notification of buy-back - CUV		05/09/24	15.7KB	Share
CUV	Update - Notification of buy-back - CUV		04/09/24	15.7KB	Share
CUV	CLINUVEL Investor Webinar		30/08/24	63.5KB	Share
CUV	Corporate Governance Statement		29/08/24	212.76KB	Share
CUV	Appendix 4G		29/08/24	263.77KB	Share
CUV	Investor Presentation	PRICE SENSITIVE	29/08/24	183.4KB	Share
CUV	CLINUVEL delivers increases in annual revenue, profit	PRICE SENSITIVE	29/08/24	101.68KB	Share
CUV	Dividend/Distribution - CUV		29/08/24	13.5KB	Share
CUV	Appendix 4E and Annual Report to Shareholders 2024	PRICE SENSITIVE	29/08/24	12MB	Share
CUV	Ceasing to be a substantial holder		23/08/24	823.24KB	Share
CUV	Becoming a substantial holder		22/08/24	1009.13KB	Share
CUV	Vitiligo and Operational Update	PRICE SENSITIVE	21/08/24	94.43KB	Share
CUV	Annual Results Webinar		19/08/24	62.39KB	Share
CUV	Ceasing to be a substantial holder		15/08/24	1.47MB	Share
CUV	Becoming a substantial holder		13/08/24	1.58MB	Share
CUV	Ceasing to be a substantial holder		13/08/24	1.48MB	Share
CUV	Becoming a substantial holder		09/08/24	1.91MB	Share
CUV	Change of Company Secretary		06/08/24	63.48KB	Share
CUV	Ceasing to be a substantial holder		01/08/24	1.35MB	Share
CUV	Becoming a substantial holder		30/07/24	1.55MB	Share
CUV	Notification of cessation of securities - CUV		05/07/24	13.51KB	Share
CUV	Afamelanotide Assists DNA Repair Response Following UVR	PRICE SENSITIVE	05/07/24	90.5KB	Share
CUV	CLINUVEL extends Managing Director Employment Agreement	PRICE SENSITIVE	28/06/24	91.02KB	Share
CUV	Change of Company Secretary		28/06/24	57.78KB	Share
CUV	SCENESSE European Orphan Drug Designation for VP		24/06/24	83.03KB	Share
CUV	afamelanotide in fair-skinned Parkinsons patients	PRICE SENSITIVE	18/06/24	96.54KB	Share
CUV	CLINUVEL Newsletter III - June 2024		11/06/24	330.48KB	Share
CUV	Update - Notification of buy-back - CUV		05/06/24	15.7KB	Share
CUV	CLINUVEL withdraws label expansion for adolescent EPP		03/06/24	86.89KB	Share
CUV	Ceasing to be a substantial holder		24/05/24	1.03MB	Share
CUV	CLINUVEL and Valentech enter Latin American partnership		23/05/24	79.1KB	Share
CUV	Update - Notification of buy-back - CUV		14/05/24	15.7KB	Share
CUV	Becoming a substantial holder		14/05/24	1.3MB	Share
CUV	Update - Notification of buy-back - CUV		10/05/24	15.7KB	Share
CUV	Update - Notification of buy-back - CUV		09/05/24	15.69KB	Share
CUV	Update - Notification of buy-back - CUV		06/05/24	15.7KB	Share
CUV	Update - Notification of buy-back - CUV		03/05/24	15.7KB	Share
CUV	Syd Capital Markets Briefing Presentation		01/05/24	4.01MB	Share
CUV	SCENESSE European Orphan Drug Designation for XP		29/04/24	88.75KB	Share
CUV	Notification of cessation of securities - CUV		29/04/24	12.86KB	Share
CUV	Update - Notification of buy-back - CUV		29/04/24	15.7KB	Share
CUV	Ceasing to be a substantial holder		26/04/24	856.04KB	Share
CUV	CLINUVEL expands global leadership team		22/04/24	76.98KB	Share
CUV	Change to executive management		15/04/24	63.29KB	Share
CUV	Update - Notification of buy-back - CUV		12/04/24	15.7KB	Share
CUV	Update - Notification of buy-back - CUV		10/04/24	15.69KB	Share
CUV	Update - Notification of buy-back - CUV		09/04/24	15.68KB	Share
CUV	Becoming a substantial holder		09/04/24	1.22MB	Share
CUV	Notification of cessation of securities - CUV		04/04/24	12.69KB	Share
CUV	CLINUVEL Newsletter II - March 2024		20/03/24	257.3KB	Share
CUV	Update - Notification of buy-back - CUV		18/03/24	13.65KB	Share
CUV	Notification of buy-back - CUV		14/03/24	13.06KB	Share
CUV	CLINUVEL initiates on market share buy-back program	PRICE SENSITIVE	14/03/24	89.87KB	Share
CUV	New case of SCENESSE efficacy in vitiligo presented at AAD	PRICE SENSITIVE	11/03/24	362.39KB	Share
CUV	SCENESSE Presented at American Academy of Dermatology		08/03/24	74.91KB	Share
CUV	Ceasing to be a substantial holder		05/03/24	1.12MB	Share
CUV	SCENESSE provides photoprotection in variegate porphyria	PRICE SENSITIVE	04/03/24	195.58KB	Share
CUV	Becoming a substantial holder		28/02/24	1.69MB	Share
CUV	Final Director's Interest Notice		27/02/24	188.5KB	Share
CUV	Half Year Results Webinar Recording		23/02/24	58.64KB	Share
CUV	CLINUVEL Delivers Increased Revenues, Solid Earnings		22/02/24	107.14KB	Share
CUV	CUV Appendix 4D Half Year Report	PRICE SENSITIVE	22/02/24	570.89KB	Share
CUV	Director Resignation		21/02/24	67.94KB	Share
CUV	CEO Letter to Shareholders		16/02/24	103.23KB	Share
CUV	Half Year Results Investor Webinar		16/02/24	59.78KB	Share
CUV	Change in substantial holding		31/01/24	1.58MB	Share
CUV	CLINUVEL Newsletter 1 - January 2024		16/01/24	256.64KB	Share
CUV	Chair Elect Letter		14/12/23	106.04KB	Share
CUV	Change to Registered Office		07/12/23	129.35KB	Share
CUV	Notification of cessation of securities - CUV		27/11/23	21.49KB	Share
CUV	Change of Director's Interest Notice		27/11/23	526.02KB	Share
CUV	Application for quotation of securities - CUV		27/11/23	25.55KB	Share
CUV	CLINUVEL Newsletter V - November 2023		24/11/23	481.47KB	Share
CUV	Sydney Vitiligo Presentation		10/11/23	874.94KB	Share
CUV	Final Director's Interest Notice		02/11/23	190.98KB	Share
CUV	CLINUVEL Appoints New Chair		31/10/23	135.75KB	Share
CUV	Results of Meeting		31/10/23	276.04KB	Share
CUV	CEO Presentation AGM		31/10/23	1.94MB	Share
CUV	Chair's Address		31/10/23	160.97KB	Share
CUV	CLINUVEL starts global Phase III vitiligo study		18/10/23	233.67KB	Share
CUV	CLINUVEL Newsletter IV - October 2023		06/10/23	245.17KB	Share
CUV	Board Changes after AGM		29/09/23	141.26KB	Share
CUV	Notice of Annual General Meeting/Proxy Form		29/09/23	577.45KB	Share
CUV	Change of Director's Interest Notice		20/09/23	321.36KB	Share
CUV	CEO Letter to Shareholders		19/09/23	192.64KB	Share
CUV	CLINUVEL Confirms AGM Date		13/09/23	117.29KB	Share

CUV Canadian New Drug Submission for SCENESSE in EPP filed
01/10/24	PRICE SENSITIVE	78.42KB	Share
CUV Update - Notification of buy-back - CUV
27/09/24		15.7KB	Share
CUV Update - Notification of buy-back - CUV
26/09/24		15.7KB	Share
CUV SCENESSE data to be presented at global porphyria conference
20/09/24		67.18KB	Share
CUV Update - Notification of buy-back - CUV
19/09/24		15.7KB	Share
CUV Notice of Annual General Meeting/Proxy Form
13/09/24		446.2KB	Share
CUV Change of AGM Time of Meeting
13/09/24		62.86KB	Share
CUV Initial Director's Interest Notice - Pearl Grimes
10/09/24		233.67KB	Share
CUV Initial Director's Interest Notice - Guy van Dievoet
10/09/24		230.29KB	Share
CUV Initial Director's Interest Notice - Matthew Pringle
10/09/24		230.05KB	Share
CUV Update - Notification of buy-back - CUV
10/09/24		15.7KB	Share
CUV Chair's letter to Shareholders
09/09/24		103.42KB	Share
CUV CLINUVEL Board Renewal, Expansion
06/09/24		80.49KB	Share
CUV Update - Notification of buy-back - CUV
06/09/24		15.7KB	Share
CUV Update - Notification of buy-back - CUV
05/09/24		15.7KB	Share
CUV Update - Notification of buy-back - CUV
04/09/24		15.7KB	Share
CUV CLINUVEL Investor Webinar
30/08/24		63.5KB	Share
CUV Corporate Governance Statement
29/08/24		212.76KB	Share
CUV Appendix 4G
29/08/24		263.77KB	Share
CUV Investor Presentation
29/08/24	PRICE SENSITIVE	183.4KB	Share
CUV CLINUVEL delivers increases in annual revenue, profit
29/08/24	PRICE SENSITIVE	101.68KB	Share
CUV Dividend/Distribution - CUV
29/08/24		13.5KB	Share
CUV Appendix 4E and Annual Report to Shareholders 2024
29/08/24	PRICE SENSITIVE	12MB	Share
CUV Ceasing to be a substantial holder
23/08/24		823.24KB	Share
CUV Becoming a substantial holder
22/08/24		1009.13KB	Share
CUV Vitiligo and Operational Update
21/08/24	PRICE SENSITIVE	94.43KB	Share
CUV Annual Results Webinar
19/08/24		62.39KB	Share
CUV Ceasing to be a substantial holder
15/08/24		1.47MB	Share
CUV Becoming a substantial holder
13/08/24		1.58MB	Share
CUV Ceasing to be a substantial holder
13/08/24		1.48MB	Share
CUV Becoming a substantial holder
09/08/24		1.91MB	Share
CUV Change of Company Secretary
06/08/24		63.48KB	Share
CUV Ceasing to be a substantial holder
01/08/24		1.35MB	Share
CUV Becoming a substantial holder
30/07/24		1.55MB	Share
CUV Notification of cessation of securities - CUV
05/07/24		13.51KB	Share
CUV Afamelanotide Assists DNA Repair Response Following UVR
05/07/24	PRICE SENSITIVE	90.5KB	Share
CUV CLINUVEL extends Managing Director Employment Agreement
28/06/24	PRICE SENSITIVE	91.02KB	Share
CUV Change of Company Secretary
28/06/24		57.78KB	Share
CUV SCENESSE European Orphan Drug Designation for VP
24/06/24		83.03KB	Share
CUV afamelanotide in fair-skinned Parkinsons patients
18/06/24	PRICE SENSITIVE	96.54KB	Share
CUV CLINUVEL Newsletter III - June 2024
11/06/24		330.48KB	Share
CUV Update - Notification of buy-back - CUV
05/06/24		15.7KB	Share
CUV CLINUVEL withdraws label expansion for adolescent EPP
03/06/24		86.89KB	Share
CUV Ceasing to be a substantial holder
24/05/24		1.03MB	Share
CUV CLINUVEL and Valentech enter Latin American partnership
23/05/24		79.1KB	Share
CUV Update - Notification of buy-back - CUV
14/05/24		15.7KB	Share
CUV Becoming a substantial holder
14/05/24		1.3MB	Share
CUV Update - Notification of buy-back - CUV
10/05/24		15.7KB	Share
CUV Update - Notification of buy-back - CUV
09/05/24		15.69KB	Share
CUV Update - Notification of buy-back - CUV
06/05/24		15.7KB	Share
CUV Update - Notification of buy-back - CUV
03/05/24		15.7KB	Share
CUV Syd Capital Markets Briefing Presentation
01/05/24		4.01MB	Share
CUV SCENESSE European Orphan Drug Designation for XP
29/04/24		88.75KB	Share
CUV Notification of cessation of securities - CUV
29/04/24		12.86KB	Share
CUV Update - Notification of buy-back - CUV
29/04/24		15.7KB	Share
CUV Ceasing to be a substantial holder
26/04/24		856.04KB	Share
CUV CLINUVEL expands global leadership team
22/04/24		76.98KB	Share
CUV Change to executive management
15/04/24		63.29KB	Share
CUV Update - Notification of buy-back - CUV
12/04/24		15.7KB	Share
CUV Update - Notification of buy-back - CUV
10/04/24		15.69KB	Share
CUV Update - Notification of buy-back - CUV
09/04/24		15.68KB	Share
CUV Becoming a substantial holder
09/04/24		1.22MB	Share
CUV Notification of cessation of securities - CUV
04/04/24		12.69KB	Share
CUV CLINUVEL Newsletter II - March 2024
20/03/24		257.3KB	Share
CUV Update - Notification of buy-back - CUV
18/03/24		13.65KB	Share
CUV Notification of buy-back - CUV
14/03/24		13.06KB	Share
CUV CLINUVEL initiates on market share buy-back program
14/03/24	PRICE SENSITIVE	89.87KB	Share
CUV New case of SCENESSE efficacy in vitiligo presented at AAD
11/03/24	PRICE SENSITIVE	362.39KB	Share
CUV SCENESSE Presented at American Academy of Dermatology
08/03/24		74.91KB	Share
CUV Ceasing to be a substantial holder
05/03/24		1.12MB	Share
CUV SCENESSE provides photoprotection in variegate porphyria
04/03/24	PRICE SENSITIVE	195.58KB	Share
CUV Becoming a substantial holder
28/02/24		1.69MB	Share
CUV Final Director's Interest Notice
27/02/24		188.5KB	Share
CUV Half Year Results Webinar Recording
23/02/24		58.64KB	Share
CUV CLINUVEL Delivers Increased Revenues, Solid Earnings
22/02/24		107.14KB	Share
CUV CUV Appendix 4D Half Year Report
22/02/24	PRICE SENSITIVE	570.89KB	Share
CUV Director Resignation
21/02/24		67.94KB	Share
CUV CEO Letter to Shareholders
16/02/24		103.23KB	Share
CUV Half Year Results Investor Webinar
16/02/24		59.78KB	Share
CUV Change in substantial holding
31/01/24		1.58MB	Share
CUV CLINUVEL Newsletter 1 - January 2024
16/01/24		256.64KB	Share
CUV Chair Elect Letter
14/12/23		106.04KB	Share
CUV Change to Registered Office
07/12/23		129.35KB	Share
CUV Notification of cessation of securities - CUV
27/11/23		21.49KB	Share
CUV Change of Director's Interest Notice
27/11/23		526.02KB	Share
CUV Application for quotation of securities - CUV
27/11/23		25.55KB	Share
CUV CLINUVEL Newsletter V - November 2023
24/11/23		481.47KB	Share
CUV Sydney Vitiligo Presentation
10/11/23		874.94KB	Share
CUV Final Director's Interest Notice
02/11/23		190.98KB	Share
CUV CLINUVEL Appoints New Chair
31/10/23		135.75KB	Share
CUV Results of Meeting
31/10/23		276.04KB	Share
CUV CEO Presentation AGM
31/10/23		1.94MB	Share
CUV Chair's Address
31/10/23		160.97KB	Share
CUV CLINUVEL starts global Phase III vitiligo study
18/10/23		233.67KB	Share
CUV CLINUVEL Newsletter IV - October 2023
06/10/23		245.17KB	Share
CUV Board Changes after AGM
29/09/23		141.26KB	Share
CUV Notice of Annual General Meeting/Proxy Form
29/09/23		577.45KB	Share
CUV Change of Director's Interest Notice
20/09/23		321.36KB	Share
CUV CEO Letter to Shareholders
19/09/23		192.64KB	Share
CUV CLINUVEL Confirms AGM Date
13/09/23		117.29KB	Share

REFRESH

1 2 3 4 5 6

(20min delay)
Last $14.52		Change 0.500(3.57%)		Mkt cap ! $727.1M

Open	High	Low	Value	Volume
$14.26	$14.65	$14.03	$3.232M	223.8K

Buyers (Bids)

No.	Vol.	Price($)
1	385	$14.50

Sellers (Offers)

Price($)	Vol.	No.
$14.57	520	1

View Market Depth

No.	Vol.	Price($)
1	385	14.500
1	773	14.470
1	773	14.440
2	1773	14.420
1	773	14.390

Price($)	Vol.	No.
14.570	520	1
14.590	169	1
14.600	1398	1
14.610	773	1
14.620	708	1

Last trade - 16.10pm 01/10/2024 (20 minute delay)


Last $14.57		Change 0.500 ( 3.46 %)
Open	High	Low	Volume
$14.26	$14.64	$14.18	16612
Last updated 15.59pm 01/10/2024 ?

CUV (ASX) Chart

CLINUVEL PHARMACEUTICALS LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories